Depigmentation therapy
Authors:
- 1 March 2001
- journal article
- research article
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 14 (1) , 29-34
Abstract
Depigmentation therapy is a treatment option for patients with widespread, treatment-resistant vitiligo. The most commonly employed technique is the application of monobenzylether of hydroquinone (MBEH), also known as monobenzone, to areas with residual pigment. Prior to instituting therapy, the patient must be aware of the cost, treatment time course, risk of distant sites of depigmentation, probable permanency of depigmentation, side effects such as contact dermatitis, and the potential for repigmentation via follicular melanocytes. The social ramifications of depigmentation therapy also must be discussed, especially for patients with skin types IV and V. The sequential use of 4-methoxyphenol and Q-switched ruby laser also has been reported as a successful form of depigmentation therapy.Keywords
This publication has 13 references indexed in Scilit:
- Different Populations of Melanocytes Are Present in Hair Follicles and EpidermisPigment Cell Research, 1996
- Dermatitis produced by applications of monobenzone in patients with active vitiligoArchives of Dermatology, 1985
- Diminished contact sensitivity response in vitiliginous skinArchives of Dermatology, 1984
- Corneal and Conjunctival Effects of Monobenzone in Patients With VitiligoArchives of Ophthalmology (1950), 1983
- Monobenzylether of hydroquinone.British Journal of Dermatology, 1977
- Evaluation of MonobenzoneJAMA, 1962
- Leukomelanoderma Subsequent to the Application of Monobenzyl Ether of HydroquinoneA.M.A. Archives of Dermatology, 1958
- TREATMENT OF MELANIN HYPERPIGMENTATIONJAMA, 1953
- Effect of Monobenzyl Hydroquinone on Oxidase Systems In Vivo and In VitroJournal of Investigative Dermatology, 1941
- OCCUPATIONAL LEUKODERMAJAMA, 1939